To infer clinically significant latent relationships between drug-cell signatures and disease signatures, we investigated the gene expression signatures of the GSE89127 (EML4-ALK-positive NCI-H3122 NSCLC cells treated with crizotinib) and GSE31210 (patients with EML4-ALK-positive NSCLC) datasets (Supplementary Fig. 1a–d). This evidence concerns the gene EML4 and non-small cell lung carcinoma.